Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2002-2-5
pubmed:abstractText
Docetaxel (DOC) is a novel microtubule polymerizing agent, with superior antiproliferative properties as compared to paclitaxel. DOC is therefore a potential therapeutic tool for the prevention of restenosis following angioplasty. However, DOC has systemic toxicity such as leukocytopenia, which occurs in a dose-dependent manner. To minimize such adverse effects, we carried out local delivery of low-dose DOC directly to injured vessel sites.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0008-6363
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
53
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
481-6
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed:year
2002
pubmed:articleTitle
Local delivery of low-dose docetaxel, a novel microtubule polymerizing agent, reduces neointimal hyperplasia in a balloon-injured rabbit iliac artery model.
pubmed:affiliation
National Cardiovascular Center, Division of Cardiology, Department of Medicine, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan. syasuda@hsp.ncvc.go.jp
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't